Topical nifedipine 0.3% plus lidocaine 1.5% for uncomplicated hemorrhoids
Official title: Observational Study on the Use of Topical Nifedipine 0.3% and Lidocaine 1.5% in Acute Uncomplicated Hemorrhoidal Disease
Run by Cardarelli Hospital · NCT07295886 · Data updated 2026-11-12
This will try topical nifedipine 0.3% plus lidocaine 1.5% applied rectally and perianally twice daily to reduce symptoms in adults with uncomplicated acute hemorrhoids.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Cardarelli Hospital Academic / other |
| Locations | 1 site (Naples) |
| Status | Recruiting |
| Started | September 2, 2025 |
| Main results expected | May 2, 2026 |
| Study ends | May 2, 2026 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07295886 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with a clinical or anoscopic diagnosis of acute hemorrhoidal disease (Goligher grade II–IV) who started topical nifedipine 0.3% plus lidocaine 1.5% within the past 5 days and can give informed consent are eligible.
✕Probably not a fit
Patients with complicated hemorrhoids (thrombosis or strangulation), coagulopathies, active cancer, on anticoagulants/chemotherapy, severe cardiovascular instability, pregnancy/breastfeeding, or known allergy to lidocaine are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, observational, single-center study of patients who are already receiving topical nifedipine 0.3% plus lidocaine 1.5% as part of routine care. Participants will apply the ointment twice daily for at least 21 days and complete four assessments over about 30 days (baseline, day 10 phone call, day 21 in-person visit, day 30 phone call). The primary outcome is change in the Hemorrhoidal Disease Symptom Score (HDSS), with secondary measures including changes in prolapse grade, quality of life, and prevention of thrombosis. Data will be entered into a web-based electronic database by study staff at the Cardarelli Hospital center in Naples, Italy.
Why it matters
Potential benefit: If effective, the topical combination could speed symptom relief, reduce prolapse severity, and lower the need for invasive procedures.
How similar studies have gone: Topical calcium-channel blockers like nifedipine have shown benefit in anal fissures, but evidence specifically for nifedipine plus lidocaine in hemorrhoidal disease is limited and largely based on small or real-world studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients aged 18-75 years. * Clinical or anoscopic diagnosis of acute hemorrhoidal disease with prolapse severity between Grade II and IV (Goligher), possibly associated with external congestion. * Patients who started treatment with nifedipine 0.3% + lidocaine 1.5% within the past 5 days. * Availability of clinical evaluations at treatment initiation (proctologic visit and HDSS, SHS-HD, VAS scales). * Ability to understand the informed consent. * Signed informed consent. Exclusion Criteria: * Acute hemorrhoidal disease complicated by thrombosis or strangulation. * Coagulopathies. * Active neoplastic disease. * Treatment with anticoagulants and/or chemotherapeutic agents. * Hypersensitivity to active substances, especially lidocaine (and other amide-type local anesthetics) or excipients. * Severe hypotensive states or cardiovascular insufficiency. * Pregnancy or breastfeeding. * Participation in clinical trials involving investigational drugs.
Where it's running
-
Azienda Ospedaliera "Antonio Cardarelli", Napoli
Naples, Italy Recruiting
Study contacts
- Study coordinator: Antonio Brillantino, MD, PhD
- Email: antonio.brillantino@gmail.com
- Phone: +393290119127
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hemorrhoid Artery Embolization (HAE) for Bleeding Internal Hemorrhoids: A Real-World Registry
This registry collects real-world data to see if hemorrhoid artery embolization helps adults with symptomatic internal hemorrhoids that haven’t improved with standard care.
-
Comparing latex and non-latex bands for treating hemorrhoids
This study is testing whether non-latex bands work as well as latex bands for treating hemorrhoids in adults and looking at any side effects they might cause.
-
SHAPE vs. Milligan-Mordon hemorrhoidectomy for advanced hemorrhoids
This trial tests whether Skin-Sparing Hemorrhoidectomy and PExy (SHAPE) works as well as the conventional Milligan-Morgan procedure for adults with severe hemorrhoids.
-
Total Coumarin botanical cream for psoriasis vulgaris
This trial will try a botanical Total Coumarin cream applied twice daily for 8 weeks to see if it helps adults with mild to moderate psoriasis.
-
Lignocaine versus GTN ointment for pain after hemorrhoidectomy
This test compares lignocaine ointment and 0.2% glyceryl trinitrate (GTN) ointment to see which provides better pain relief for adults after hemorrhoidectomy.
-
Neoven (Ruscus aculeatus 225 mg) capsules for adults with stage II–III hemorrhoids
This test will see if Neoven (Ruscus aculeatus 225 mg) capsules reduce symptoms in adults aged 18–45 with stage II–III hemorrhoids.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.